Expanding Holi’s Digital Treatment Platform: Securing €3 Million to Fight Global Obesity

Holi, a HealthTech startup based in Poland, has recently secured €3 million in Seed funding to expand its digital obesity clinic and venture into new European markets. The funding round was led by 4growth VC from Poland, along with contributions from YZR Capital and Heartfelt Capital from Germany, as well as a group of business angels.

Paweł Seweryn, the Founder & CEO of Holi, emphasized the importance of continuity and the integration of various medical specialties in obesity treatment. He expressed the company’s goal of providing a comprehensive solution that brings about long-term changes in metabolic health. With the new funding, Holi aims to scale its operations internationally, starting with markets in Southern and Eastern Europe, which have shown a strong interest in private healthcare and telemedicine.

The Seed funding places Holi in the midst of a dynamic European HealthTech landscape focused on digital obesity care in the year 2025. Other companies in the same sector have also attracted significant investments this year. For instance, Numan from the UK raised €51.6 million to expand its digital health platform for preventative care, including obesity management. Similarly, Doctor.One from Poland secured €4 million to extend its chronic care model, covering obesity and other conditions, to Western European markets. Ciloa from France obtained €6.5 million for developing exosome-based therapies targeting metabolic diseases like obesity and type 2 diabetes.

These examples highlight the growing investor interest in obesity treatment and metabolic care innovation. The fact that another Polish startup, Doctor.One, received funding in the same year underscores Poland’s increasing presence in the European digital healthcare sector.

Holi, founded in 2023, operates as a digital obesity clinic that combines multidisciplinary medical care with technology to support lifestyle changes and pharmacotherapy. The company offers access to GLP-1-based pharmacotherapy, including medications like Ozempic and Wegovy. Through its mobile app and specialist platform, Holi delivers personalized treatment plans and continuous patient monitoring, focusing on improving metabolic health by addressing the root causes of obesity.

The recently secured funds will be utilized to expand Holi’s medical infrastructure and enhance its technological capabilities, including diagnostics integration, GLP-1 tracking, automation of care processes, and new engagement features to sustain patient motivation. Data provided by the company shows that patients using the platform achieve an average 17% reduction in body weight after 12 months, surpassing the results of pharmacotherapy alone.

According to WHO data, over 800 million people worldwide are currently living with obesity, with nearly two billion classified as overweight. Obesity poses a significant global public health challenge, contributing to more than 200 medical conditions and increasing pressure on healthcare systems.

Krzysztof Bachta, the Managing Partner at 4growth VC, commended Holi for its efficient care model that delivers clinically proven outcomes at a reasonable price point. He highlighted the company’s focus on medical impact and smart product design as key factors that influenced their investment decision.

The European obesity treatment market is estimated to be worth €40-50 billion, with private healthcare spending on the rise as GLP-1 drugs gain popularity among patients. Markus Feuerecker, the Co-founder and Managing Partner at YZR Capital, praised Holi for its progress in clinical outcomes and operational execution, leading to a significant increase in their support for the company.

In conclusion, Holi’s innovative approach to obesity treatment and metabolic care, coupled with its focus on data-driven precision and expert intervention, positions it as a key player in the evolving European HealthTech landscape. The company’s commitment to delivering better outcomes through a hybrid model of data and AI, supported by medical expertise, reflects the future direction of healthcare innovation.